Enliven CFO receives options and RSU grants

Enliven Therapeutics reported new equity awards for its Chief Financial Officer, Benjamin Hohl.

Rhea-AI Filing Summary

Enliven Therapeutics reported new equity awards for its Chief Financial Officer, Benjamin Hohl. He received stock options for 150,000 shares at an exercise price of $0.00 per share and 25,000 restricted stock units, each representing one share of common stock.

The option award vests over four years, with one-quarter vesting on February 12, 2027 and the remainder monthly thereafter, as long as he continues as a service provider. The RSUs vest on a similar multi-year schedule beginning March 1, 2027, with one-quarter vesting initially and the rest in equal quarterly installments.

Insider Trade Summary

Grant/Award: 175,000 shares

Grant/Award 2 txns

Insider Hohl Benjamin

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	150,000	$0.00	$0.00
Grant/Award	Common Stock	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 150,000 contracts (Direct); Common Stock — 61,000 shares (Direct)

Footnotes (3)

1. F1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.
2. F2. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
3. F3. 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Enliven Therapeutics (ELVN) grant to its CFO?

Enliven Therapeutics granted its CFO, Benjamin Hohl, stock options for 150,000 shares and 25,000 restricted stock units. The options carry a $0.00 exercise price, and each RSU represents one share of common stock, subject to multi-year vesting conditions tied to continued service.

How do the new stock options for Enliven (ELVN) CFO vest?

The 150,000-share stock option grant vests over four years. One-quarter of the shares vest on February 12, 2027, and the remaining three-quarters vest in equal monthly installments thereafter, contingent on Benjamin Hohl continuing as a service provider through each vesting date.

What is the vesting schedule for the Enliven (ELVN) CFO RSUs?

The 25,000 RSUs vest starting March 1, 2027. One-quarter vests on that date, and 1/16 of the RSUs vests on each June 1, September 1, December 1, and March 1 afterward, provided Benjamin Hohl remains a service provider on each vesting date.

Does the Enliven (ELVN) CFO have to pay to exercise his stock options?

The disclosed stock options have an exercise price of $0.00 per share. This means Benjamin Hohl is not required to pay cash to exercise them, although exercise and settlement remain subject to standard plan terms and applicable vesting requirements.

Are the Enliven (ELVN) CFO RSUs and options immediately owned and unrestricted?

No. Both the RSUs and options are subject to vesting schedules. RSUs represent contingent rights to receive shares, and the option vests over time. Hohl must continue as a service provider through each specified date for the corresponding portion to vest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 07:49 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hohl Benjamin

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		A		25,000(1)	A	$0	61,000(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$27.16	02/12/2026		A		150,000		(3)	02/12/2036	Common Stock	150,000	$0	150,000	D

Explanation of Responses:

1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.

2. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

3. 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

	/s/ Benjamin Hohl	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.